GlassScriptPhysician profile
Mohammad Kooshkabadi
NPI 1740464189
$13,951.07
in general payments reported to CMS, 2019-2025
29 companies · $3,225 in 2025
The $3,225 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,873 · 2020: $846 · 2021: $1,364 · 2022: $2,210 · 2023: $1,860 · 2024: $1,573 · 2025: $3,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,634 · Travel and Lodging: $2,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,633.65 |
| Travel and Lodging | $2,024.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,476.56 | 2021-2025 | Micra, Capsurefix Novus Mri Surescan, Aurora Ev-Icd Mri Surescan |
| Medtronic Vascular, INC. | $3,237.07 | 2019-2020 | |
| Cvrx, INC. | $1,398.52 | 2021-2024 | Barostim Neo System |
| Abbott Laboratories | $417.92 | 2019-2022 | |
| Boston Scientific Corporation | $355.27 | 2019-2025 | Farapulse, General - Therapies, Watchman Flx |
| Pfizer INC. | $344.64 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.29 | 2019-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $332.14 | 2022-2025 | Assure Wcd |
| Atricure, INC. | $289.84 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $264.61 | 2020-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $178.85 | 2019-2024 | Xarelto |
| Heartflow, INC. | $160.37 | 2022-2024 | Ffrct |
| Sanofi-Aventis U.S. LLC | $155.96 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $144.94 | 2019-2024 | Camzyos |
| Biosense Webster, INC. | $139.97 | 2025 | Carto 3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $118.67 | 2021-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $106.76 | 2019-2024 | |
| Amgen INC. | $99.71 | 2020-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $99.68 | 2021-2023 | Farxiga, Andexxa |
| Imperative Care, INC | $51.18 | 2025 | Symphony Catheter |
| Bardy Diagnostics, INC. | $46.00 | 2019-2020 | |
| Edwards Lifesciences Corporation | $41.46 | 2019-2024 | Sapien 3 Ultra Resilia |
| Esperion Therapeutics, INC. | $40.76 | 2024-2025 | Nexletol |
| Celgene Corporation | $20.89 | 2024 | Camzyos |
| Siemens Medical Solutions USA, INC. | $19.81 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $18.46 | 2023 | Arcalyst |
| Glaxosmithkline, LLC. | $16.83 | 2025 | Shingrix, Arexvy |
| W. L. Gore & Associates, INC. | $16.74 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $14.17 | 2023 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Kooshkabadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.